Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Gianluca Spitaleri"'
Autor:
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5121-5139 (2024)
The ever-growing knowledge regarding NSCLC molecular biology has brought innovative therapies into clinical practice; however, the treatment situation in the non-metastatic setting is rapidly evolving. Indeed, immunotherapy-based perioperative treatm
Externí odkaz:
https://doaj.org/article/3ed05c0b4ba740369ca1630364d8a082
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5072-5092 (2023)
ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases. The activity of chemotherapy and immunotherapy is modest in ALK
Externí odkaz:
https://doaj.org/article/237f3ac30475444a97d7a0d94817d83b
Autor:
Ilaria Attili, Carmine Valenza, Celeste Santoro, Gabriele Antonarelli, Pamela Trillo Aliaga, Ester Del Signore, Chiara Catania, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundFollowing the introduction of immunotherapy (IO) in the first-line (1L) treatment in patients with non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK mutations, increasing real-world data depict how difficult it is to replicate
Externí odkaz:
https://doaj.org/article/b82967c179b1415b8e47bb150aadac48
Autor:
Chiara Catania, Gianluca Spitaleri, Ester Del Signore, Ilaria Attili, Davide Radice, Valeria Stati, Letizia Gianoncelli, Stefania Morganti, Filippo de Marinis
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
In February 2020, Italy became one of the first countries to be plagued by the SARS-CoV-2 pandemic, COVID-19. In March 2020, the Italian government decreed a lockdown for the whole country, which overturned communication systems, hospital organizatio
Externí odkaz:
https://doaj.org/article/c482541459014b8eae0d08837e0da789
Autor:
Filippo de Marinis, Ilaria Attili, Stefania Morganti, Valeria Stati, Gianluca Spitaleri, Letizia Gianoncelli, Ester Del Signore, Chiara Catania, Cristiano Rampinelli, Emanuela Omodeo Salè, Lorenzo Spaggiari, Fabrizio Mastrilli, Antonio Passaro
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
A novel coronavirus causing severe acute respiratory syndrome (SARS), named SARS-CoV-2, was identified at the end of 2019. The spread of coronavirus disease 2019 (COVID-19) has progressively expanded from China, involving several countries throughout
Externí odkaz:
https://doaj.org/article/b166a3ec616645e09a8354bb34f21503
Autor:
Alice T. Shaw, Jeffrey A. Engelman, Beow Y. Yeap, Luc Friboulet, Katherine Schultz, Gianluca Spitaleri, Filippo de Marinis, Chiara Lazzari, Aziah Ahmad, Benjamin J. Solomon, Tomasso De Pas, Daniel S.W. Tan, Justin F. Gainor
Figure Legends - Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23f524a1d2a849d57164aa21d42a09fd
https://doi.org/10.1158/1078-0432.22460670
https://doi.org/10.1158/1078-0432.22460670
Autor:
Alice T. Shaw, Jeffrey A. Engelman, Beow Y. Yeap, Luc Friboulet, Katherine Schultz, Gianluca Spitaleri, Filippo de Marinis, Chiara Lazzari, Aziah Ahmad, Benjamin J. Solomon, Tomasso De Pas, Daniel S.W. Tan, Justin F. Gainor
Supplementary Table 1. Summary of Interval Systemic Anticancer Therapies Received by ALK-Positive Patients Between Crizotinib and Ceritinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97222405a06e66c87fabdbba45449281
https://doi.org/10.1158/1078-0432.22460661.v1
https://doi.org/10.1158/1078-0432.22460661.v1
Autor:
Alice T. Shaw, Jeffrey A. Engelman, Beow Y. Yeap, Luc Friboulet, Katherine Schultz, Gianluca Spitaleri, Filippo de Marinis, Chiara Lazzari, Aziah Ahmad, Benjamin J. Solomon, Tomasso De Pas, Daniel S.W. Tan, Justin F. Gainor
Supplementary Figure 1. Individual swimmer plots for each patient who underwent a post-crizotinib/pre-ceritinib biopsy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3bff6ffdaad946378b92cc6d3daeab
https://doi.org/10.1158/1078-0432.22460667.v1
https://doi.org/10.1158/1078-0432.22460667.v1
Autor:
Alice T. Shaw, Jeffrey A. Engelman, Beow Y. Yeap, Luc Friboulet, Katherine Schultz, Gianluca Spitaleri, Filippo de Marinis, Chiara Lazzari, Aziah Ahmad, Benjamin J. Solomon, Tomasso De Pas, Daniel S.W. Tan, Justin F. Gainor
Supplementary Figure 2. Overall survival (OS) for anaplastic lymphoma kinase (ALK)-positive patients with brain metastases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d262333b4dcc27ea4b6a9f7f32c108e
https://doi.org/10.1158/1078-0432.22460664.v1
https://doi.org/10.1158/1078-0432.22460664.v1
Autor:
Claus Garbe, Dario Neri, Hans D. Menssen, Eveline Trachsel, Manuela Kaspar, Valeria Lovato, Kathrin Schwager, Leonardo Giovannoni, Annaelisa Tasciotti, Reinerio González-Iglesias, Annette Pflugfelder, Antonella Romanini, Gianluca Spitaleri, Filippo de Braud, Benjamin Weide, Thomas K. Eigentler
Purpose: L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of fibronectin, a tumor angiogenesis marker, and of human interleukin-2 (IL2). L19-IL2 delivers IL2 to the tumor site exploiting the selective expressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515cb8edb1fb08d6e25954005b6ec308
https://doi.org/10.1158/1078-0432.c.6520914.v1
https://doi.org/10.1158/1078-0432.c.6520914.v1